PACIRA BIOSCIENCES, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
PACIRA BIOSCIENCES, INC. (PCRX) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2022-11-03
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-09-30 was 0.00 shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-06-30 was 0.00 shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2022-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2021-09-30 was 0.00 shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2017 was 0.00 shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2016 was 0.00 shares, a 100.00% decline from fiscal 2015.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2015 was 3.11M shares.
- PACIRA BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2014 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2022-09-30 | 0.00 shares 10-Q · filed 2022-11-03 | 0.00 shares 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | 0.00 shares 10-Q · filed 2022-08-03 | 0.00 shares 10-Q · filed 2022-08-03 | ||
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-04 | |||
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-03 | 51.00K shares 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 0.00 shares 10-Q · filed 2022-08-03 | 76.00K shares 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | 152.00K shares 10-Q · filed 2022-05-04 | |||
| 2020-09-30 | 0.00 shares 10-Q · filed 2021-11-03 | 0.00 shares 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | 0.00 shares 10-Q · filed 2021-08-03 | 0.00 shares 10-Q · filed 2021-08-03 | ||
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-04 | |||
| 2017-12-31 | 0.00 shares 10-K · filed 2018-02-28 | |||
| 2016-12-31 | 0.00 shares 10-K · filed 2018-02-28 | |||
| 2016-09-30 | 0.00 shares 10-Q · filed 2016-11-02 | 0.00 shares 10-Q · filed 2016-11-02 | ||
| 2016-06-30 | 0.00 shares 10-Q · filed 2016-08-04 | 0.00 shares 10-Q · filed 2016-08-04 | ||
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-02 | |||
| 2015-12-31 | 3.11M shares 10-K · filed 2018-02-28 | |||
| 2015-09-30 | 2.84M shares 10-Q · filed 2016-11-02 | 3.26M shares 10-Q · filed 2016-11-02 | ||
| 2015-06-30 | 3.28M shares 10-Q · filed 2016-08-04 | 3.46M shares 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | 3.65M shares 10-Q · filed 2016-05-02 | |||
| 2014-12-31 | 0.00 shares 10-K · filed 2017-03-01 | 0.00 shares 10-K · filed 2016-02-25 | ||
| 2014-09-30 | 0.00 shares 10-Q · filed 2015-10-27 | 0.00 shares 10-Q · filed 2015-10-27 | ||
| 2014-06-30 | 0.00 shares 10-Q · filed 2015-07-30 | 0.00 shares 10-Q · filed 2015-07-30 | ||
| 2014-03-31 | 0.00 shares 10-Q · filed 2015-04-30 | |||
| 2013-12-31 | 0.00 shares 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |